24 August 2021: Clinical Research
Different Doses of Nalbuphine Combined with Dexmedetomidine in Laparoscopic Oophorocystectomy
Xiaofen Liu ABCDEF , Jie Song BCDF , Yang Zhang BCDF , Ye Zhang BCDF , Xianwen Hu CDFG*DOI: 10.12659/MSM.930197
Med Sci Monit 2021; 27:e930197
Table 1 Characteristics of all patients.
| Variables | Total, n=219 | LND, n=55 | MND, n=54 | HND, n=55 | Control, n=55 | P value |
|---|---|---|---|---|---|---|
| Age, years | 36.34±8.20 | 37.34±8.15 | 36.61±8.35 | 35.72±7.46 | 35.69±8.86 | 0.677 |
| BMI, kg/m | 21.27±2.15 | 21.29±2.14 | 21.15±2.23 | 21.69±2.14 | 20.95±2.07 | 0.329 |
| Cyst diameter, cm | 6.03±0.57 | 6.10±0.50 | 6.06±0.55 | 5.95±0.62 | 6.00±0.61 | 0.543 |
| Pathological types, n (%) | 0.841 | |||||
| Serous cyst | 61 (27.85) | 17 (30.91) | 14 (25.93) | 15 (27.27) | 15 (27.27) | |
| Mucinous cyst | 55 (25.11) | 13 (23.64) | 16 (29.63) | 12 (21.82) | 14 (25.45) | |
| Endometrioma | 51 (23.29) | 15 (27.27) | 11 (20.37) | 13 (23.64) | 12 (21.82) | |
| Teratoma | 52 (23.74) | 10 (18.18) | 13 (24.07) | 15 (27.27) | 14 (25.45) | |
| Operative time, min | 46.71±9.85 | 48.43±9.36 | 45.86±10.29 | 44.67±9.57 | 47.84±9.97 | 0.164 |
| Blood loss, mL | 44.32±5.76 | 43.67±5.62 | 44.77±5.46 | 43.19±6.04 | 45.64±5.73 | 0.112 |
| BMI – body mass index; LND – low-dose nalbuphine and dexmedetomidine; MDN – middle-dose nalbuphine and dexmedetomidine; HND – high-dose nalbuphine and dexmedetomidine. | ||||||